The Predictive and prognostic relevance of P53 oncogene in patients with serous epithelial ovarian cancer | ||
| Benha Medical Journal | ||
| Volume 37, Issue 1, May 2020 PDF (826.13 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bmfj.2020.23459.1212 | ||
| Authors | ||
| Hind Elgenedi* 1; Inas Abdelhalim2; Mahfouz Abdel-Aziz Eita3; Maiy Al Shahat4; Mohamed Arafa5 | ||
| 1Clinical Oncology Department,Faculty of Medicine, Mansoura university, Dakahleyia, Egypt | ||
| 2Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University, Egypt | ||
| 3Clinical Oncology Department, Faculty of Medicine, Mansoura University | ||
| 4Clinical Oncology Department, Faculty of Medicine Mansoura University | ||
| 5Clinical Pathology Department, Faculty of Medicine , Mansoura University | ||
| Abstract | ||
| Background: Ovarian cancer is a common malignant gynecological tumor that is difficult to diagnose early, progresses rapidly, and causes high mortality. Aims of our study: to assess the relationship of P53 with other clinico-pathological parameters and the effect of P53 on patients’ out come. Subjects and methods: This study was conducted at Clinical Oncology and Nuclear Medicine Department with Pathology Department, Faculty of Medicine, Mansoura University. The study was carried out on 50 patients with serous epithelial ovarian cancer presented to receive adjuvant treatments following a primary surgery and were followed from the first day after surgery, follow-up started on January, 2012 till February, 2016. P53 expression was assessed immunohistochemically on formalin-fixed paraffin-embedded tissues, and Secondary red Envision system. patients were given adjuvant treatment(s) according to according to NCCN guidelines. The primary endpoint of the study was loco regional recurrence, and distant metastasis. At the end of the follow-up period, the patient clinico-pathological data and patient outcome were collected. Results: we found that P53 negative tumors have a better OS & DFS at 3 year than with P53 positive tumors, but not reached statistically significant differences ( P value = 0.04 & 0.05 respectively). Conclusion: Our results showed no statically significant difference between P53 expression OS & DFS,needs to be evaluated in other study including large number of patients before using it as a marker for the outcome in these tumors. | ||
| Keywords | ||
| P53; ovarian cancer; Disease-free survival; Prognostic markers | ||
|
Statistics Article View: 24 PDF Download: 9 |
||
